David U'Prichard, Ph.D. Joins Invitrogen Corp.'s Board of Directors; David McCarty Rotates off Board after Nearly Five Years of Service.Business Editors/Health/Medical Writers BIOWIRE2K CARLSBAD, Calif.--(BUSINESS WIRE)--May 19, 2004 Invitrogen Corp. (Nasdaq:IVGN), a provider of essential life science technologies for disease research and drug discovery, today announced that its stockholders have elected David U'Prichard, Ph.D., to the company's board of directors, effective April 29, 2004. "We are honored to have Dr. U'Prichard join Invitrogen's board of directors," said Gregory T. Lucier, Invitrogen's chairman, president and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. . "The vast life science experience Dr. U'Prichard brings to our company is invaluable as we move toward becoming the preeminent partner in drug discovery, development and production." Dr. U'Prichard is currently a venture partner with global private equity provider, Apax Partners Inc. and president of Druid Druid Member of a learned class of priests, teachers, and judges among the ancient Celtic peoples. The Druids instructed young men, oversaw sacrifices, judged quarrels, and decreed penalties; they were exempt from warfare and paid no tribute. Consulting LLC (Logical Link Control) See "LANs" under data link protocol. LLC - Logical Link Control , a consulting firm Noun 1. consulting firm - a firm of experts providing professional advice to an organization for a fee consulting company business firm, firm, house - the members of a business organization that owns or operates one or more establishments; "he worked for a specializing in the pharmaceutical and biotechnology industries. Previously, he was CEO of 3-Dimensional Pharmaceuticals between 1999 and 2003, overseeing the company's initial public offering and eventual acquisition by Johnson & Johnson Pharmaceutical Research and Development LLC. From 1997 to 1999, Dr. U'Prichard served as chairman of research and development at SmithKline Beecham. Before that, he held various R&D management positions at ICI/Zeneca, finally as executive vice president and international research director from 1993 to 1997. In addition, Dr. U'Prichard holds a bachelors degree in pharmacology from the University of Glasgow The University of Glasgow (Scottish Gaelic: Oilthigh Ghlaschu, Latin: Universitas Glasguensis) was founded in 1451, in Glasgow, Scotland. , as well as a Ph.D. in pharmacology from the University of Kansas The University of Kansas (often referred to as KU or just Kansas) is an institution of higher learning in Lawrence, Kansas. The main campus resides atop Mount Oread. . His academic experience also includes a post as an associate professor of pharmacology and neurobiology Neurobiology Study of the development and function of the nervous system, with emphasis on how nerve cells generate and control behavior. The major goal of neurobiology is to explain at the molecular level how nerve cells differentiate and develop their at Northwestern University Medical School and a postdoctoral fellowship at The Johns Hopkins University Johns Hopkins University, mainly at Baltimore, Md. Johns Hopkins in 1867 had a group of his associates incorporated as the trustees of a university and a hospital, endowing each with $3.5 million. Daniel C. . He was a co-founder and head of R&D at Nova Pharmaceuticals Corp. (Baltimore) from 1983 to 1986, and has held academic appointments at The Johns Hopkins University, University of Maryland University of Maryland can refer to:
http://upenn.edu/. Address: Philadelphia, PA, USA. . He is also an honorary professor at the University of Glasgow. Dr. U'Prichard is chairman of the board of Oxagen Limited (Oxford, U.K.) and is a director of various companies including Guilford Pharmaceuticals Inc. (Baltimore) and Lynx Therapeutics Inc. (San Francisco). Rotating off the board of directors is David E. McCarty, who has been a member for nearly five years. McCarty joined the board following Invitrogen's acquisition of NOVEX in 1999. Previously, McCarty was president and CEO of NOVEX and Alexon Biomedical bi·o·med·i·cal adj. 1. Of or relating to biomedicine. 2. Of, relating to, or involving biological, medical, and physical sciences. . "We would like to extend our most sincere gratitude to David McCarty as he departs our board of directors," continued Lucier. "He has been an integral part of the growth this company has experienced over the past five years, and his leadership has positioned Invitrogen to become one of the most important organizations to emerge from the biotechnology industry." About Invitrogen Invitrogen Corp. (Nasdaq:IVGN) provides products and services that support academic and government research institutions and pharmaceutical and biotech companies worldwide in their efforts to improve the human condition. The company provides essential life science technologies for disease research, drug discovery, and commercial bio-production. Invitrogen's own research and development efforts are focused on breakthrough innovation in all major areas of biological discovery including functional genomics, proteomics, bioinformatics and cell biology -- placing Invitrogen's products in nearly every major laboratory in the world. Founded in 1987, Invitrogen has headquarters in Carlsbad and conducts business in more than 70 countries around the world. The company globally employs approximately 3,800 scientists and other professionals. For more information about Invitrogen visit the company's Web site at www.invitrogen.com. Safe Harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. Statement Certain statements contained in this press release are considered "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995, and it is Invitrogen's intent that such statements be protected by the safe harbor created thereby. Forward-looking statements include, but are not limited to: 1) Dr. U'Prichard's vast life science experience will facilitate the move toward becoming the preeminent partner in drug discovery, development and production; 2) As a result of McCarty's leadership, Invitrogen is positioned to become one of the most important organizations to emerge for the biotechnology industry. Potential risks and uncertainties include, but are not limited to, the risks: a) there may be changes in Invitrogen's strategic direction while Dr. U'Prichard serves on the board; b) Invitrogen may not realize the level of success that would term it one of the most important organizations to emerge from the biotechnology industry, as well as other risks and uncertainties detailed from time to time in Invitrogen's Securities and Exchange Commission filings. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion